Volume 16 Issue 6, June 2019

Use of an absorbable antibacterial envelope is a safe and effective strategy for reducing major infections related to cardiac implantable electronic devices.

PB2452, a specific reversal agent for ticagrelor, provided rapid and sustained reversal of ticagrelor’s antiplatelet effects in healthy volunteers.

A regimen that includes a P2Y₁₂ inhibitor plus apixaban without aspirin results in less bleeding and hospitalizations, without significant differences in ischaemic events, than use of regimens that include a vitamin K antagonist, aspirin or both

Two prespecified analyses of the DECLARE–TIMI 58 trial show that in patients with type 2 diabetes mellitus, dapagliflozin has greater cardiovascular benefit in those with heart failure with reduced ejection fraction at baseline and in those with prior myocardial infarction

In the COACT trial, a strategy of immediate coronary angiography and percutaneous coronary intervention did not improve outcomes following successful resuscitation after out-of-hospital cardiac arrest in the absence of ST-segment elevation myocardial infarction.

In patients with symptomatic atrial fibrillation presenting to the emergency department, immediate cardioversion was noninferior to delayed cardioversion in re-establishing a normal rhythm after 4 weeks.

Dual therapies combining a calcium-channel blocker with an angiotensin-converting enzyme (ACE) inhibitor or thiazide diuretic are more effective at lowering blood pressure in black African patients than the combination of an ACE inhibitor and a thiazide diuretic.

AIBP-mediated cholesterol efflux promotes the specification of haematopoietic stem and progenitor cells (HSPCs) in embryogenesis and induces adult HSPC expansion in hypercholesterolaemic conditions, mediated by SREBP2-regulated activation of Notch signalling.

This Review summarizes the preclinical data on the role of T cell co-stimulatory and co-inhibitory pathways in cardiovascular disease (CVD) and discusses the therapeutic potential of targeting co-stimulation and inhibition molecules to treat CVD, as well as the evidence of an association between the use of immune checkpoint inhibitors and cardiovascular toxicity.

Transient receptor potential (TRP) channels are a family of 28 nonselective cationic channels that are heterogeneously expressed in different regions and cell types of the heart. In this Review, the authors summarize the various physiological and pathological cardiac processes in which TRP channels are involved.

In this Review, the authors summarize mechanoregulated pathways in cardiac myocytes and fibroblasts that lead to altered gene expression and cell remodelling under physiological and pathophysiological conditions. They also discuss the use of systems modelling to discover new therapies to target mechanosignalling in heart disease.